Abdul Mannan: Why Apixaban May Be the Safer Choice for Acute VTE
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“For years, we’ve been prescribing both apixaban and rivaroxaban for acute VTE as if they were identical twins.
They’re not.
The COBRRA trial just published in NEJM (Castellucci LA et al., 2026) is the first randomised head-to-head comparison of these two DOACs in acute symptomatic VTE.
And the results are clear.
Here’s what the data shows:
- Clinically Relevant Bleeding: 3.3 percent with apixaban versus 7.1 percent with rivaroxaban
- Major Bleeding: 0.4 percent versus 2.4 percent (RR 0.16 – that is not a small difference)
- Recurrent VTE: 1.1 percent versus 1.0 percent (no meaningful difference)
Same protection. Less bleeding. That’s a win for patients.
This was a pragmatic, open-label, blinded-endpoint trial with 1:1 allocation across acute proximal DVT and PE.
Real-world design. Blinded outcome adjudication. Three months follow-up.
The limitation worth noting: it excluded active cancer, pregnancy, severe renal impairment, and extreme body weight.
So this applies to your standard acute VTE patient, not every patient.
But for that standard patient?
The choice just got easier.
Apixaban appears to be the safer DOAC for acute VTE treatment when bleeding risk matters. And bleeding risk always matters.
Does this change your practice?
Are you already defaulting to apixaban, or does your institution still treat them as equivalent?
Drop your thoughts below.”
Other posts featuring Abdul Mannan on Hemostasis Today.
-
Jun 24, 2026, 16:09Jimi Olaghere: The Future of Sickle Cell Disease Research Starts With Collaboration
-
Jun 24, 2026, 16:03Von Willebrand Disease as a Common Yet Under-Recognised Bleeding Disorder – EHC
-
Jun 24, 2026, 15:57Maia Meier: Women with Bleeding Disorders Reach the Summit of Mont Blanc
-
Jun 24, 2026, 15:40Annette Bowyer: The Emerging Role of Extravascular Factor VII in Haemostasis
-
Jun 24, 2026, 13:50Tijjani Balas: Why Early Detection of DVT Matters
-
Jun 24, 2026, 13:43Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
-
Jun 24, 2026, 13:37Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot Miss
-
Jun 24, 2026, 13:32Jecko Thachil: Understanding the Clinical Spectrum of Vitamin B12
-
Jun 24, 2026, 13:32Namrata Singh: Beyond Low Platelets – Understanding What Triggers ITP